Cantor Fitzgerald reiterates overweight rating on Zai Lab stock

Cantor Fitzgerald reiterated its Overweight rating on Zai Lab (ZLAB) with a $56 price target, citing confidence in ZL-1310's potential for accelerated approval for ES-SCLC following positive ASCO data showing a 60-70% objective response rate. Analysts project peak sales of $1-2 billion for ZL-1310, anticipating Zai Lab will reach cash flow positivity by year-end, while other firms have recently initiated coverage or adjusted ratings with varying price targets amid geopolitical and market uncertainties.

Analysis

Cantor Fitzgerald maintained an Overweight rating on Zai Lab (NASDAQ:ZLAB) with a $56.00 price target, substantially above its current $31.19 trading price, reflecting strong confidence in the ZL-1310 (DLL3-ADC) treatment for extensive stage small cell lung cancer (ES-SCLC). This optimism follows recent ASCO conference data from 74 patients, which detailed RP3D selection and Phase 3 trial design, increasing prospects for an accelerated approval by 2027. ZL-1310 demonstrated a notable objective response rate (ORR) of 60-70%, markedly superior to Imdelltra's 35-40%, supporting potential peak sales of $1-2 billion. Zai Lab, which has seen a 73% stock return over the past year, is also approaching cash flow positivity by year-end. Other analysts offer varied perspectives: Scotiabank initiated coverage with a Sector Outperform rating and a $55 target, citing global potential, while BofA Securities downgraded Zai Lab to Neutral, raising its price target to $36.10, acknowledging near-term product challenges but recognizing long-term pipeline strength including Optune and Bemarituzumab. Cantor Fitzgerald also anticipates Zai Lab achieving profitability by Q4 2025, despite geopolitical tensions and market volatility.

Key Decisions for Investors

• Investors should consider the significant potential upside for Zai Lab, highlighted by Cantor Fitzgerald's $56 price target and ZL-1310's promising 60-70% ORR in ES-SCLC, especially as the company approaches cash flow positivity by year-end.
• Closely monitor upcoming clinical trial data, Phase 3 progress, and regulatory milestones for ZL-1310, as these are key catalysts that could validate the pathway to accelerated approval by 2027 and significantly impact valuation.
• Balance the bullish outlook from analysts like Cantor Fitzgerald and Scotiabank against BofA Securities' more cautious near-term stance, and factor in the existing geopolitical and market risks when evaluating or adjusting positions in Zai Lab.